Humanigen Inc (HGENQ)

[DonDonDonDon]

It's going to be interesting how the GM-CSF information that came out in UK study affects things. Lenz is given at an early stage of severe in the trial. So basically when a moderate patient is progressing to severe. When the trials started, it obviously wasn't practical to give an expensive mab to every mild patient. But the UK study found that the patients who eventually become severe and die have elevated GM-CSF even when they are mild without many symptoms. So it might not be impractical to give lenz early since it will only be a small fraction of mild patients who have elevated GM-CSF. Right now, the equipment doesn't exist to test every mild patient's blood. But those scanners are going to be built. Humanigen might even be in talks with the scientists from the UK trial about doing a collaboration where they test and HGEN treats. Lenz could end up being given to mild, moderate, and severe patients with the treatment coming earlier and earlier as more scanners are built. More government funding for trials should be forthcoming.